Sep. 16 at 11:46 AM
$PATH Check out Longeveron!
Phase 1 - All 10 babies were alive after 1 year with no heart transplant, standard of care, survival is 70-80%...follow up of 10 babies after 5 years all are alive with no heart transplant....SOC is 3 heart surgeries....treatment is SOC (3 heart surgeries) + the drug (laromestrocel) given after 2nd heart surgery
LGVN market cap
$20 million -
$2 billion annual potential revenues (only US and Europe (untapped)) times a p/s of 8 ->
$16 billion market cap, for only HLHS (unmet medical need...Hypoplastic Left Heart Syndrome...HLHS phase 2 results September 2026)...40 babies after 1 year (20:20)
HLHS program may be eligible for PRV (priority review voucher) upon BLA approval (valued between
$150-200 million)
Incredible phase 2 Alzheimer’s results, granted RMAT fast-track - in talks with potential partners for phase 3
50 patents
60 patents pending
